Jump to content Jump to main menu Jump to sub menu


17 December 2009 - QED receives routine inspection from MHRA

QED was routinely inspected by the UK Regulatory Authority, the MHRA, at its offices in Milton Keynes.  QED are pleased to announce that there were no critical findings from the inspection.

4 November 2009 - QED featured in CRfocus

QED are proud to announce the publication of an interview with QED’s Sue Ollier, Director UK Operations and Paul Thompson, Director Business Development in November’s edition of  Clinical Research focus (CRfocus).  CRfocus is the Institute of Clinical Research’s (ICR) peer-reviewed journal, published every month.  The interview entitled  “Exploring an Innovative CRO Business Model” took place at QED’s new Head Quarters and can be viewed here.

15 September 2009 - Two Become One: QED integration increases operational strength

QED Clinical Services has recently joined forces with QED Partnership, another highly experienced UK based CRO. The coming together of the two companies under the QED Clinical Services umbrella means that the merged organization can now provide further expertise, capacity and enhanced quality in the conduct of clinical trials. The two companies were already long term partners, sharing many similarities and hence this is a highly complementary pairing. The resulting enhanced QED Clinical Services organization can now draw on the vast experience of new Senior Management team members, such as Susan Ollier, BSc, MRQA, HonFICR, CSci and David Ollier BSc, MICR. Susan was previously the chair of the Institute of Clinical Research (ICR) for 2 years and a member of the ICR Board for 6 years and David has an extensive clinical background with focus on working closely with the NHS. The QED Partnership team also bring a diverse customer base ranging from large pharmaceutical sponsors to small Biotech which complement the numerous existing QED Clinical sponsors. Furthermore the team possess a wealth of experience in Research Governance, Auditing and Training within the NHS which will allow QED Clinical to expand its non-commercial sponsor business significantly.

18 November 2009 - QED awarded pioneering Phase I Oncology trial

QED is proud to announce that it has been selected to run a complex phase I oncology trial at key sites in the United States, Spain and Belgium.  The study in patients with advanced solid tumours will be split into two parts with a safety extension phase. 

Paul Thompson, Director Business Development for QED, commented “We are very pleased to have been awarded this very important and challenging study.  The trial further enhances our strong oncology trial experience and gives us an opportunity to be involved in some truly pioneering and innovative clinical research”.

15 October 2009 - QED office move

QED’s ongoing success has led the company to continue to expand the size of its team, resulting in the demand for more office space.  As a result the company has relocated to larger premises still within the Milton Keynes area.

Thomas Ogorka, QED CEO, commented “The move to larger premises reflects our consistently strong performance and continued growth. Our success and expansion is further credit to QED considering the challenges facing the wider CRO industry and reflects the determination, expertise and professionalism of our staff. We are excited about the office move and the increase in space will enable us to continue to expand in the future.”

QED’s new address details can be found here.

9 September 2009 - QED shortlisted in Best CRO category of Scrip Awards

QED is proud to announce that it has been shortlisted in the category of “Best CRO” in the 5th Annual Scrip awards. This competition, organized by Scrip World Pharmaceutical News, a major provider of news and analysis for the global biopharmaceutical industry, promotes new standards of excellence and celebrates achievements that reflect the innovating nature of the industry. QED has been nominated alongside several leading global CROs by an illustrious panel of pharmaceutical industry experts.

Scrip’s Best CRO Award is given in recognition of the key role CROs play in drug development. QED are confident that their success in building trust and solid working relationships, and its development as a highly innovative and flexible organisation, make it a crucial CRO partner for the pharmaceutical industry.